Literature DB >> 5329342

A trial of mithramycin in the treatment of advanced malignant disease.

I A Sewell, H Ellis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 5329342      PMCID： PMC2008976          DOI： 10.1038/bjc.1966.32

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  4 in total

1.  MITHRAMYCIN IN THE TREATMENT OF EMBRYONAL CANCER.

Authors:  S KOFMAN; T J MEDREK; R W ALEXANDER
Journal:  Cancer       Date:  1964-07       Impact factor: 6.860

2.  MITHRAMYCIN IN THE TREATMENT OF DISSEMINATED TESTICULAR NEOPLASMS.

Authors:  J H BROWN; B J KENNEDY
Journal:  N Engl J Med       Date:  1965-01-21       Impact factor: 91.245

3.  Clinical trial with mithramycin.

Authors:  P W SPEAR
Journal:  Cancer Chemother Rep       Date:  1963-05

4.  Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use.

Authors:  D A KARNOFSKY; J H BURCHENAL; G C ARMISTEAD; C M SOUTHAM; J L BERNSTEIN; L F CRAVER; C P RHOADS
Journal:  AMA Arch Intern Med       Date:  1951-04
  4 in total
  4 in total

1.  Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.

Authors:  Tristan M Sissung; Phoebe A Huang; Ralph J Hauke; Edel M McCrea; Cody J Peer; Roberto H Barbier; Jonathan D Strope; Ariel M Ley; Mary Zhang; Julie A Hong; David Venzon; Jonathan P Jackson; Kenneth R Brouwer; Patrick Grohar; Jon Glod; Brigitte C Widemann; Theo Heller; David S Schrump; William D Figg
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

2.  Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.

Authors:  Mahadev Rao; Scott M Atay; Vivek Shukla; Young Hong; Trevor Upham; R Taylor Ripley; Julie A Hong; Mary Zhang; Emily Reardon; Patricia Fetsch; Markku Miettinen; Xinmin Li; Cody J Peer; Tristan Sissung; William D Figg; Assunta De Rienzo; Raphael Bueno; David S Schrump
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

3.  A clinical trial of mithramycin in the treatment of advanced malignant disease.

Authors:  M Baum
Journal:  Br J Cancer       Date:  1968-06       Impact factor: 7.640

Review 4.  Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer.

Authors:  David Schweer; J Robert McCorkle; Jurgen Rohr; Oleg V Tsodikov; Frederick Ueland; Jill Kolesar
Journal:  Biomedicines       Date:  2021-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.